CHNA
Loncar China BioPharma ETFCHNA Fund Description
CHNA tracks a tier-weighted index of companies directly involved in the growth of China’s pharmaceutical and biotech industry.
CHNA Factset Analytics Insight
CHNA targets China’s pharmaceutical and biotech (biopharma) sector. The fund includes pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers or distributors of biopharma products, and biopharma service providers. It is worth noting that manufacturers of pharmaceutical ingredients are excluded, as the fund focuses on innovation in the sector. CHNA uses a tiered weighting system. Starting from equal weight, all qualified constituents are assigned a weight adjustment based on market cap. Large cap stocks get a 140% adjustment, midcaps 100%, and small-caps 70%. For this exposure, CHNA charge a fee in line with its closest competitors, although still at a price worth consideration.
CHNA MSCI ESG Analytics Insight
Loncar China BioPharma ETF has an MSCI ESG Fund Rating of BBB based on a score of 4.99 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.
The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. Loncar China BioPharma ETF ranks in the 31st percentile within its peer group and in the 89th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.
CHNA Charts And Performance
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
CHNA Summary Data
CHNA Portfolio Data
CHNA Index Data
CHNA Portfolio Management
CHNA Tax Exposures
CHNA Fund Structure
CHNA Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of CHNA. CHNA is rated a 1 out of 5.
CHNA Tradability
CHNA Sector/Industry Breakdown
CHNA
CHNA Top 10 Holdings[View All]
CHNA Countries
CHNA
CHNA Regions
CHNA
CHNA Economic Development
CHNA
CHNA Performance Statistics
CHNA MSCI ESG Ratings
CHNA Benchmark Comparison Summary
CHNA
CHNA Benchmark Comparison Market Cap Size
CHNA
The data and information contained herein is not intended to be investment or tax advice. A reference to a particular investment or security, a credit rating, or any observation concerning a security or investment provided in the ETF.com Service is not a recommendation to buy, sell, or hold such investment or security or to make any other investment decisions. You should not use such information for purposes of any actual transaction without consulting an investment or tax professional.
ETF.com DOES NOT TAKE RESPONSIBILITY FOR YOUR INVESTMENT OR OTHER ACTIONS NOR SHALL ETF.com HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE, FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF ANY INFORMATION PROVIDED BY ETF.com OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON SUCH INFORMATION OR ETF.com.
[ETF.com DOES NOT PROVIDE ANY RESEARCH OPINIONS.] ETF.com MAKES NO REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, PRODUCTS OR SERVICES CONTAINED HEREIN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.
Data provider:
Terms of Use
MSCI ESG Research LLC’s ("MSCI ESG") Fund Metrics products (the "Information") provide environmental, social and governance data with respect to underlying securities within more than 24,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.